Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy
- Company
- Vor Biopharma Inc. (VOR)
- Indication
- Primary Sjogren's Disease
Other upcoming events for VOR
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.